IN THE CLAIMS

1. (currently amended) A method for identifying a compound which binds to a 14189 polypeptide having a kinase activity, comprising the steps of:

a) contacting a 14189 polypeptide with a test compound; and

b) determining whether the 14189 polypeptide binds to the test compound, wherein the 14189 polypeptide comprises a polypeptide selected from the group consisting of:

~~i) a polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence which is at least 97% identical to the nucleic acid molecule of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,~~

~~ii)~~ i) a polypeptide encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,

~~iii)~~ ii) a polypeptide having the amino acid sequence of SEQ ID NO:2,

~~iv)~~ iii) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2),

~~v)~~ iv) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide,

~~vi)~~ v) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2) and a non-kinase polypeptide, and

~~vii)~~ vi) a fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.

2. (original) The method of claim 1, wherein the binding of the test compound to the 14189 polypeptide is detected by a method selected from the group consisting of:

a) detection of binding by direct detecting of test compound/polypeptide binding;

b) detection of binding using a competition binding assay;

c) detection of binding using an assay for 14189 kinase activity; and

d) detection of binding using a two-hybrid assay.

3. (original) The method of claim 1, wherein the 14189 polypeptide is expressed in a cell and the test compound is contacted with the cell expressing the 14189 polypeptide.

4. (original) The method of claim 1, wherein the compound is identified in a cell-free assay.

5. (original) The method of claim 1, wherein the 14189 polypeptide is immobilized on a solid surface.

6. (original) The method of claim 1, wherein the test compound is directly or indirectly labeled.

7. (currently amended) A method for identifying a compound which binds to a 14189 polypeptide having a kinase activity, comprising:

a) contacting an assay mixture comprised of a 14189 polypeptide and a known compound that binds a 14189 polypeptide with a test compound; and

b) determining the ability of the test compound to modulate the activity of a kinase target molecule, wherein activity of the kinase target molecule indicates binding of the kinase target molecule with the 14189 polypeptide, wherein the 14189 polypeptide comprises a polypeptide selected from the group consisting of:

~~i) a polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence which is at least 97% identical to the nucleic acid molecule of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,~~

~~ii)~~ i) a polypeptide encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,

~~iii)~~ ii) a polypeptide having the amino acid sequence of SEQ ID NO:2,

~~iv)~~ iii) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2),

~~v)~~ iv) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide,

~~vi)~~ v) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2), and a non-kinase polypeptide, and

~~vii)~~ vi) a fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.

8. (original) The method of claim 7, wherein the activity of the kinase target molecule is selected from the group consisting of: a) cellular second messenger activity, b) catalytic/enzymatic activity, c) reporter gene induction, and d) cellular growth, differentiation or proliferation.

9. (currently amended) A method for identifying a compound which binds to a 14189 polypeptide having a kinase activity, comprising:

a) contacting an assay mixture comprised of a 14189 polypeptide and a known compound that binds a 14189 polypeptide with a test compound; and

b) determining the ability of the test compound to preferentially bind to the 14189 polypeptide, wherein the 14189 polypeptide comprises a polypeptide selected from the group consisting of:

~~i) a polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence which is at least 97% identical to the nucleic acid molecule of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,~~

~~ii)~~ i) a polypeptide encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, nucleotides 48-1682 of SEQ ID NO:1, or the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333,

~~iii)~~ ii) a polypeptide having the amino acid sequence of SEQ ID NO:2,

~~iv)~~ iii) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2),

~~v)~~ iv) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide,

~~vi)~~ v) a polypeptide comprising the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2) and a non-kinase polypeptide, and

~~vii)~~ vi) a fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.

10. (original) The method of claim 9, wherein the 14189 polypeptide is immobilized on a solid surface.

11. (original) The method of claim 9, wherein the test compound is immobilized on a solid surface.

12. (original) The method of claim 9, wherein the binding of the test compound to the 14189 polypeptide is detected by a method selected from the group consisting of: a) detection of binding by direct detecting of test compound/polypeptide binding; b) detection of binding using a competition binding assay; c) detection of binding using an assay for 14189 kinase activity; and d) detection of binding using a two-hybrid assay.

13. (new) The method of claim 1 wherein the 14189 polypeptide comprises the polypeptide encoded by the nucleic acid comprising the nucleotide sequence of SEQ ID NO:1.

14. (new) The method of claim 1 wherein the 14189 polypeptide comprises the polypeptide encoded by nucleotides 48-1682 of SEQ ID NO:1.

15. (new) The method of claim 1 wherein the 14189 polypeptide comprises the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333.

16. (new) The method of claim 1 wherein the 14189 polypeptide comprises the polypeptide having the amino acid sequence of SEQ ID NO:2.

17. (new) The method of claim 1 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2).

18. (new) The method of claim 1 wherein the 14189 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide.

19. (new) The method of claim 1 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2) and a non-kinase polypeptide.

20. (new) The method of claim 1 wherein the 14189 polypeptide comprises the fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.

21. (new) The method of claim 7 wherein the 14189 polypeptide comprises the polypeptide encoded by the nucleic acid comprising the nucleotide sequence of SEQ ID NO:1.

22. (new) The method of claim 7 wherein the 14189 polypeptide comprises the polypeptide encoded by nucleotides 48-1682 of SEQ ID NO:1.

23. (new) The method of claim 7 wherein the 14189 polypeptide comprises the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333.

24. (new) The method of claim 7 wherein the 14189 polypeptide comprises the polypeptide having the amino acid sequence of SEQ ID NO:2.

25. (new) The method of claim 7 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2).

26. (new) The method of claim 7 wherein the 14189 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide.

27. (new) The method of claim 7 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2) and a non-kinase polypeptide.

28. (new) The method of claim 7 wherein the 14189 polypeptide comprises the fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.

29. (new) The method of claim 9 wherein the 14189 polypeptide comprises the polypeptide encoded by the nucleic acid comprising the nucleotide sequence of SEQ ID NO:1.

30. (new) The method of claim 9 wherein the 14189 polypeptide comprises the polypeptide encoded by nucleotides 48-1682 of SEQ ID NO:1.

31. (new) The method of claim 9 wherein the 14189 polypeptide comprises the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2333.

32. (new) The method of claim 9 wherein the 14189 polypeptide comprises the polypeptide having the amino acid sequence of SEQ ID NO:2.

33. (new) The method of claim 9 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2).

34. (new) The method of claim 9 wherein the 14189 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2 and a non-kinase polypeptide.

35. (new) The method of claim 9 wherein the 14189 polypeptide comprises the serine kinase domain of 14189 (amino acid residues 13-304 of SEQ ID NO:2) and a non-kinase polypeptide.

36. (new) The method of claim 9 wherein the 14189 polypeptide comprises the fusion polypeptide encoded by a nucleic acid comprising a nucleotide sequence which encodes SEQ ID NO:2 operably linked to a nucleotide sequence which encodes a non-kinase polypeptide.